On Tuesday, 3304 stocks advanced, 981 declined and 151 remained unchanged on Bombay Stock Exchange with advance decline ratio of 3.36 indicating a positive closing. Today, nearly 536 stocks gained more than 4.5%, while around 914 stocks advanced over 3%, reflecting broad-based strength across the market. After remaining in the bearish zone for 50 consecutive sessions, Moneylife’s Market Breadth Indicators have now risen into neutral territory as the number of stocks holding above their 20-, 50-, and 200-day EMAs pushed higher, signaling a shift in internal momentum. If these moves sustain or extend further, they could meaningfully alter market breadth, paving the way for a transition toward emerging strength and potentially reversing the prolonged weakness. If such moves sustain or extend further it could alter the market breadth. The trend of the major indices on Tuesday’s trading is given in the table below.
On NSE, 58 securities advanced and closed at a new 52-week high whereas 68 securities sank to close at their new 52-week lows. Nifty Infrastructure, Nifty Pharma and Nifty Energy among the biggest gainers.
Zensar Technologies (+0.07%) issued an official clarification denying any talks to acquire Mastek, directly countering recent media speculation. The IT services firm emphasised that there is no material impact on its operations and moved swiftly to reassure investors and stakeholders with transparent communication.
Transgene Biotek (-7.96%) disclosed to receiving a SEBI prohibitory order of ₹38 lakh from a June 2022 adjudication. The order has frozen all bank accounts and prohibited disposal of assets, causing complete operational paralysis, including suspension of salary payments. Though the company filed an appeal with the Securities Appellate Tribunal in Oct 2022, recovery proceedings have stalled all business activities.
Sun Pharma Advanced Research Company (SPARC) (+4.58%) announced that the US FDA has granted a Rare Pediatric Disease Priority Review Voucher (PRV) linked to the approval of Sezaby®, marking a key regulatory milestone. The PRV programme incentivizes innovation in rare pediatric treatments, with vouchers tradable or redeemable for priority review of future drug applications, shortening FDA timelines.
RITES (+1.46%) signed an MoU with Steel Authority of India Ltd (SAIL) to provide specialised railway services supporting SAIL’s steel plants and mining operations. The collaboration covers wet leasing of locomotives, higher schedule maintenance of SAIL‑owned diesel‑electric locomotives, and O&M support, leveraging RITES’ expertise in railway operations and asset management.
Zaggle Prepaid Ocean Services (+6.69%) signed a strategic agreement with Dr Batra’s Positive Health Clinic Pvt Ltd, deploying its Zoyer platform to strengthen enterprise digital solutions in healthcare. The contract is domestic and structured as a formal agreement, valid until terminated per terms, indicating a long‑term engagement.
Solar Industries India (+4.50%) posted a strong quarter with net profit rising 41.7% y‑o‑y to ₹446.3 crore (vs. ₹315 crore last year). Revenue from operations grew 29.2% y‑o‑y to ₹2,548.3 crore (vs. ₹1,973 crore), reflecting robust demand momentum.
Varun Beverages (-3.26%) posted a net profit of ₹251.7 crore in Q3FY25‑26, registering a 36% increase y‑o‑y from ₹185 crore in Q3FY24‑25. Revenue for the quarter rose 13.5% y‑o‑y to ₹4,334.7 crore, up from ₹3,817.6 crore in Q3FY24‑25.
Indoco Remedies (+10.66%) reported its Q3FY25‑26 results with revenue increasing 8.5% y‑o‑y to ₹445.4 crore. The company posted a net loss of ₹29.8 crore in Q3FY25‑26.
Campus Activewear (-0.79%) reported its Q3FY25-26 results with revenue from operations at ₹588.61 crore, registering a 14.3% increase y o y compared to ₹514.80 crore in Q3FY24 25. Net profit for Q3FY25-26 rose strongly to ₹63.68 crore, delivering a 37.0% increase y-o-y over ₹46.47 crore in Q3FY24‑25.
The top gainers and top losers of the major indices are given in the table below:
The closing values of the major Asian indices are given in the table below:
